Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.14.5375 on March 17 2008

Journal of Clinical Oncology, Vol 26, No 11 (April 10), 2008: pp. 1810-1816
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Miller, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Miller, K. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Harold J. Burstein, Anthony D. Elias, Hope S. Rugo, Melody A. Cobleigh, Antonio C. Wolff, Peter D. Eisenberg, Mary Lehman, Bonne J. Adams, Carlo L. Bello, Samuel E. DePrimo, Charles M. Baum, Kathy D. Miller

From the Dana-Farber Cancer Institute, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; University of California San Francisco, San Francisco; California Cancer Care Inc, Greenbrae; Pfizer Inc, La Jolla; TRACON Pharmaceuticals Inc, San Diego, CA; Rush University Medical Center, Chicago, IL; Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD; and the Indiana University Simon Cancer Center, Indianapolis, IN

Corresponding author: Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA, 02115; e-mail: hburstein{at}partners.org

Purpose Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, stem cell factor receptor (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC).

Patients and Methods Sixty-four patients previously treated with an anthracycline and a taxane received sunitinib 50 mg/d in 6-week cycles (4 weeks on, then 2 weeks off treatment). The primary end point was objective response rate. Plasma samples were obtained for pharmacokinetic and biomarker analysis.

Results Seven patients achieved a partial response (median duration, 19 weeks), giving an overall response rate of 11%. Three additional patients (5%) maintained stable disease for ≥ 6 months. Median time to progression and overall survival were 10 and 38 weeks, respectively. Notably, responses occurred in triple negative tumors and HER2-positive, trastuzumab-treated patients. Thirty-three patients (52%) required dose interruption during ≥ 1 cycle, and 25 patients required dose reduction (39%). Thirty-six patients (56%) had dose modifications due to adverse events (AEs). Treatment was associated with increases in plasma VEGF and decreases in soluble VEGFRs and KIT. The most common AEs were fatigue, nausea, diarrhea, mucosal inflammation, and anorexia. Most AEs were mild to moderate (grade 1 to 2) in severity and were effectively managed with dose delays or reductions.

Conclusion Sunitinib is active in patients with heavily pretreated MBC. Most AEs were of mild-to-moderate severity and manageable with supportive treatment and/or dose modification. Further studies in breast cancer are warranted.

published online ahead of print at www.jco.org on March 17, 2008.

Supported by Pfizer Inc.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. L. Bello, M. Mulay, X. Huang, S. Patyna, M. Dinolfo, S. Levine, A. Van Vugt, M. Toh, C. Baum, and L. Rosen
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clin. Cancer Res., November 15, 2009; 15(22): 7045 - 7052.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al.
Third consensus on medical treatment of metastatic breast cancer
Ann. Onc., November 1, 2009; 20(11): 1771 - 1785.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. E. DePrimo, X. Huang, M. E. Blackstein, C. R. Garrett, C. S. Harmon, P. Schoffski, M. H. Shah, J. Verweij, C. M. Baum, and G. D. Demetri
Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure
Clin. Cancer Res., September 15, 2009; 15(18): 5869 - 5877.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone
Target-based therapies in breast cancer: current status and future perspectives
Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. M. L. Ebos, C. R. Lee, and R. S. Kerbel
Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
Clin. Cancer Res., August 15, 2009; 15(16): 5020 - 5025.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Frasci, P. Comella, M. Rinaldo, G. Iodice, M. Di Bonito, M. D'Aiuto, A. Petrillo, S. Lastoria, C. Siani, G. Comella, et al.
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer
Ann. Onc., July 1, 2009; 20(7): 1185 - 1192.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. G. Willett, D. G. Duda, E. di Tomaso, Y. Boucher, M. Ancukiewicz, D. V. Sahani, J. Lahdenranta, D. C. Chung, A. J. Fischman, G. Y. Lauwers, et al.
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
J. Clin. Oncol., June 20, 2009; 27(18): 3020 - 3026.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. T.H. Yeh and C. L. Bickford
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. Burkitt, S. Y. Chun, D. T. Dang, and L. H. Dang
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
Mol. Cancer Ther., May 1, 2009; 8(5): 1148 - 1156.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. E. Houk, C. L. Bello, D. Kang, and M. Amantea
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
Clin. Cancer Res., April 1, 2009; 15(7): 2497 - 2506.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. D. Mignogna, G. Fortuna, S. Leuci, A. Pollio, and E. Ruoppo
Sunitinib Adverse Event: Oral Bullous and Lichenoid Mucositis
Ann. Pharmacother., March 1, 2009; 43(3): 546 - 547.
[Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
S. Sinclair, A. S. Zimmer, and S. M. Swain
HER-2 Targeting Agents and Antiangiogenic Therapy: Evolution of Adjuvant Therapy in Breast Cancer
ASCO Educational Book, January 1, 2009; 2009(1): 3 - 10.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. P. Schneider, E. P. Winer, W. D. Foulkes, J. Garber, C. M. Perou, A. Richardson, G. W. Sledge, and L. A. Carey
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Clin. Cancer Res., December 15, 2008; 14(24): 8010 - 8018.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. H. Garfield, P. Wolter, P. Schoffski, A. Hercbergs, and P. Davis
Documentation of Thyroid Function in Clinical Studies With Sunitinib: Why Does It Matter?
J. Clin. Oncol., November 1, 2008; 26(31): 5131 - 5132.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online